Efficacy and Tolerability of RAP-219, a Potential First-in-class Negative Allosteric Modulator of γ8 Transmembrane AMPA Receptor Regulatory Protein: Impact on RNS Long Episodes and Clinical Seizures (S29.003)

Neurology 2026

View at publisher
Authors: William Motley, Imran Quraishi, Neal Nolan, Daniel Friedman, Patrick Landazuri, Vikram Rao, Kathryn Davis, Bradley Galer, Nancy Wyant, Martha Morrell, Arnold Gammaitoni, Jacqueline French
DOI: 10.1212/wnl.0000000000216447
Cited by: 3

Abstract

Assess the effect of RAP-219, a selective and potent transmembrane AMPA receptor regulatory protein (TARP)-γ8 negative allosteric modulator, using a novel biomarker (long episodes [LEs]) in patients with an implanted responsive neurostimulator (RNS® System, NeuroPace) for drug-resistant focal seizures (FOS).

Fields of Study & Subjects

Neuroscience and Neuropharmacology Research Pharmacological Receptor Mechanisms and Effects Nicotinic Acetylcholine Receptors Study

Publication details

Journal / source
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
106
Issue
11_Supplement_1
Publication date
9 June 2026
Language
EN